{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:16Z","timestamp":1789560136866,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess cabergoline's efficacy at decreasing breast symptoms after second-trimester abortion or pregnancy loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This was a double-blinded, block-randomized superiority trial comparing cabergoline 1 mg once to placebo for preventing bothersome breast engorgement after second-trimester uterine evacuation. We enrolled pregnant people at 18\u201328 weeks of gestation who were English- or Spanish-speaking and without contraindication to the study drug. Participants completed a validated, piloted, electronic survey at baseline and at multiple timepoints through 2 weeks postprocedure to assess breast symptoms, side effects, and bother. Our primary outcome was any breast symptoms (a composite of engorgement, milk leakage, tenderness, and need for pain relief) on day 4; we planned to enroll 80 patients to show a 30% difference in breast symptoms (80% power, \u03b1=0.049). A subgroup of participants returned for serum prolactin levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      After screening 150 patients from April 2021 to June 2022, we enrolled 73 participants. Baseline demographics were balanced between groups: median gestational age was 21 weeks (range 18\u201326 weeks), 56.2% of participants were nulliparous, 34.2% self-identified as Hispanic, and 37.0% had public insurance. At baseline, reported breast symptoms were similar between groups. Among 69 participants who returned surveys on day 4, significantly fewer participants receiving cabergoline reported any breast symptoms compared with placebo (27.8% vs 97.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001) (primary outcome) and fewer reported significant bother (2.8% vs 33.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.001) (secondary outcome). These differences persisted through day 14. Reported incidence and severity of bother from side effects were similar between groups: most common were constipation, fatigue, and headache. Serum prolactin levels were similar at baseline. On day 4, mean serum prolactin level was 6.5 ng\/mL (SD 2.2) for those who received cabergoline and 18.0 ng\/mL (SD 5.9) for placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.049).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Cabergoline is an effective and well-tolerated strategy to prevent breast symptoms after second-trimester abortion or pregnancy loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04701333.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005190","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:03:45Z","timestamp":1684429425000},"page":"1115-1123","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss"],"prefix":"10.1097","volume":"141","author":[{"given":"Andrea","family":"Henkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica P.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1552-6909.12724","article-title":"Taiwanese women's experiences of lactation suppression after stillbirth","volume":"44","author":"Chen","year":"2015","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1097\/01.AOG.0000664260.95519.2e","article-title":"Breast symptoms after pregnancy loss and abortion: an observational study [abstract]","volume":"135","author":"Hagey","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5539\/gjhs.v8n9p234","article-title":"An exploration of the maternal experiences of breast engorgement and milk leakage after perinatal Loss","volume":"8","author":"Sereshti","year":"2016","journal-title":"Glob J Health Sci"},{"key":"R4-20260916","first-page":"305","article-title":"The nuts and bolts of breastfeeding: anatomy and physiology of lactation","volume":"47","author":"Sriraman","year":"2017","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0002-9378(98)70013-4","article-title":"Treatment for lactation suppression: little progress in one hundred years","volume":"179","author":"Spitz","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20260916","article-title":"Treatments for breast engorgement during lactation","author":"Zakarija-Grkovic","year":"2020","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00016349009028686","article-title":"Prevention of breast pain and milk secretion with bromocriptine after second-trimester abortion","volume":"69","author":"Andersen","year":"1990","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2007-994294","article-title":"Clinical commentary: the bromocriptine (Parlodel) controversy and recommendations for lactation suppression","volume":"13","author":"Rayburn","year":"1996","journal-title":"Am J Perinatology"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jogc.2019.03.014","article-title":"Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review","volume":"42","author":"Harris","year":"2020","journal-title":"J Obstet Gynaecol Can"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006199-196601530-00004","article-title":"Comparative effectiveness of compressional and supporting breast binders in suppressing lactation","volume":"15","author":"Bristol","year":"1966","journal-title":"Nurs Res"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0029-7844(95)00062-V","article-title":"A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss","volume":"85","author":"Janssen","year":"1995","journal-title":"Obstet Gynecol"},{"key":"R16-20260916","first-page":"93","article-title":"Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery","volume":"31","author":"Giorda","year":"1991","journal-title":"Gynecol Obstet Invest"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.302.6789.1367","article-title":"Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition","volume":"302","year":"1991","journal-title":"BMJ"},{"key":"R18-20260916","first-page":"311","article-title":"Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline","volume":"71","author":"Melis","year":"1988","journal-title":"Obstet Gynecol"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/epirev\/24.1.39","article-title":"Sample size calculations for randomized controlled trials","volume":"24","author":"Wittes","year":"2002","journal-title":"Epidemiologic Rev"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029900800102","article-title":"Multiple imputation: a primer","volume":"8","author":"Schafer","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"R21-20260916","first-page":"46","article-title":"Arrest of lactation after 2nd trimester abortion with a single dose of cabergoline in comparison with 10-day administration of teguride [in Czech]","volume":"68","author":"Pavlista","year":"2003","journal-title":"Ceska Gynekol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:35Z","timestamp":1789556615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005190"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005190","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"2022-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}